Hormone replacement therapy aggravates postmenopausal urinary incontinence.

PubMed · 16989027

Hormone replacement therapy aggravates postmenopausal urinary incontinence.

Abstract

(1) In the WHI trials, which involved more than 20 000 women, the frequency of urinary incontinence increased among postmenopausal women taking hormone replacement therapy compared with placebo. Among women who were continent at enrollment, the frequency of stress incontinence at 1 year was 16% with an oestrogen-progestin combination, compared with 9% with placebo (relative risk 1.87, 95% confidence interval: 1.61-2.18). Among women who were already incontinent, the relative risk of aggravation with hormone replacement therapy compared with placebo was about 1.40. (2) The results of another trial involving nearly 3000 women were similar. (3) Other, smaller trials failed to show any positive impact of oestrogen-progestin therapy on urinary incontinence in postmenopausal women. (4) In practice, postmenopausal hormone replacement therapy does not protect against urinary incontinence; on the contrary, it may trigger or worsen urinary incontinence.

Explore related subjects

Clinical Trials as Topic Estrogen Replacement Therapy Female Hormone Replacement Therapy Humans Postmenopause Urinary Incontinence Women's Health Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

2006. Hormone replacement therapy aggravates postmenopausal urinary incontinence.. https://pubmed.ncbi.nlm.nih.gov/16989027/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

On the exact interval estimation for the difference in paired areas under the ROC curves.

An important measure for comparison of accuracy between two diagnostic procedures is the difference in paired areas under the receiver operating characteristic (ROC) curves. Non-parametric and maximum likelihood methods have been proposed for interval estimation for the difference in paired areas under ROC curves. However, these two methods are asymptotic procedures and their performance in finite sample sizes has not been thoroughly investigated. We propose to use the concept of generalized pivotal quantities (GPQs) to construct an exact confidence interval for the difference in paired areas under ROC curves. A simulation study is conducted to empirically investigate the probability coverage and expected length of the three methods for various combinations of sample sizes, values of the area under the ROC curve and correlations. Simulation results demonstrate that the exact confidence interval based on the concept of GPQs provides not only sufficient probability coverage but also reasonable expected length. Numerical examples using published data sets illustrate the proposed method.

Clinical Trials as Topic↗

PubMed2007

An efficient test for the analysis of dichotomized variables when the reliability is known.

A difference in an outcome variable between the treatment groups in a trial does not necessarily mean that there is a difference in the number of patients who experience relevant improvement on that variable. When the relevant improvement corresponds with an outcome or change in outcome that exceeds a certain threshold, the outcome variable can be dichotomized. A responder is a patient whose outcome exceeds the threshold. Comparisons can be made between the number of responders in the two treatment groups using logistic regression, or some other method to evaluate binary outcomes. An important disadvantage of this approach is the loss of power. In general, it is more efficient to test the difference between the mean values. We developed a statistical test that compares response rates for a dichotomized variable. It requires that an estimate of the reliability of the outcome variable is available. Simulations showed that the test was valid and robust over a wide range of distributions and sample sizes. The power was greater than the power of a chi(2) test, which would enable substantial reduction in the sample size.

Clinical Trials as Topic↗

PubMed2007

Sample size determination for logistic regression revisited.

There is no consensus on the approach to compute the power and sample size with logistic regression. Some authors use the likelihood ratio test; some use the test on proportions; some suggest various approximations to handle the multivariate case. We advocate the use of the Wald test since the Z-score is routinely used for statistical significance testing of regression coefficients. The null-variance formula became popular from early studies, which contradicts modern software, which utilizes the method of maximum likelihood estimation (MLE), when the variance of the MLE is estimated at the MLE, not at the null. We derive general Wald-based power and sample size formulas for logistic regression and then apply them to binary exposure and confounder to obtain a closed-form expression. These formulas are applied to minimize the total sample size in a case-control study to achieve a given power by optimizing the ratio of controls to cases. Approximately, the optimal number of controls to cases is equal to the square root of the alternative odds ratio. Our sample size and power calculations can be carried out online at www.dartmouth.edu/ approximately eugened.

Clinical Trials as Topic↗